Zuellig Pharma teams up with Moderna to supply vaccines to Southeast Asia
Healthcare services provider in Asia Zuellig Pharma and Moderna, a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced a new partnership with Zuellig Pharma’s division, ZP Therapeutics, to supply Moderna Covid-19 vaccines to Southeast Asia, Hong Kong, Macau and Taiwan, the firms said in a press statement on Wednesday.
“We are thrilled to partner with Moderna in strengthening Thailand’s access to this important vaccine,” said Sunaiyanaa Kidkasetpaisal, head of ZP Therapeutics, Zuellig Pharma Thailand.
“ZP Therapeutics, guided by our corporate mission, is committed to making healthcare and innovative treatments more accessible to communities in Thailand and across the region,” Sunaiyanaa added.
“Our collaboration with Moderna to supply the Covid-19 vaccine in Asia reaffirms Zuellig Pharma’s commitment to help fight the global pandemic,” said Zuellig Pharma CEO John Graham.
“We are drawing upon our expertise, resources and extensive distribution network to support governments and, where allowed, private healthcare institutions across the region in implementing end-to-end vaccination programmes. Also importantly, we are working closely with governments to help them plan for the security of their vaccine supplies,” he added.
“We are proud of what the Moderna team has achieved in collaboration with our partners including Zuellig Pharma,” said Moderna CCO Corinne Le Goff. “Together with our partners, we remain focused on helping address the pandemic with our vaccine.”
Zuellig Pharma is one of the largest healthcare services groups in Asia. It provides distribution, digital and commercial services to more than 350,000 medical facilities and its more than 1,000 clients, which include the top 20 pharmaceutical companies in the world.
